Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic
| Autor: | Sophie Danel, Laure Belmont, Lise Rosencher, Jacques Cadranel, Anne-Marie Ruppert, Valérie Gounant, Bernard Milleron, C. Epaud, Armelle Lavolé, Laurence Baudrin |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Antineoplastic Agents Docetaxel Kidney Vinblastine Gastroenterology Deoxycytidine Nephrotoxicity Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Outpatient clinic Humans Radiology Nuclear Medicine and imaging Lung cancer Aged Etoposide Retrospective Studies Cisplatin Aged 80 and over business.industry Combination chemotherapy Retrospective cohort study Vinorelbine Hematology General Medicine Middle Aged medicine.disease Chemotherapy regimen Small Cell Lung Carcinoma Gemcitabine Surgery Oncology Creatinine Toxicity Fluid Therapy Female Kidney Diseases Taxoids business medicine.drug |
| Zdroj: | Bulletin du cancer. 99(4) |
| ISSN: | 1769-6917 |
| Popis: | Cisplatin is a pivotal drug in combined chemotherapy for non-small cell and small-cell lung cancers (NSCLC or SCLC), but its renal toxicity limits its use. Current guidelines recommend 24 h hydration: thus hospitalization is required. The aim of this retrospective study was to confirm the safety of short hydration before giving an intermediate-to-high dose of cisplatin in an outpatient clinic.Patients eligible had NSCLC or SCLC and were being treated with a chemotherapy regimen that included cisplatin ≥ 75 mg/m(2). They were given the same short hydration protocol for 1 day. Nephrotoxicity was defined as ≥ grade 1 according to NCIC common toxicity criteria. Predictive factors for nephrotoxicity were analyzed.Three hundred and fifty-seven consecutive patients (median age 58 years, range: 25-81) were reviewed. Twenty-one patients (6%) had ≥ grade 1 nephrotoxicity and all except one had grade 1 toxicity according to NCIC criteria for common toxicity (SC1,5 N). Predictive factors independently associated with nephrotoxicity included associated co-morbid conditions (hypertension, diabetes, heart disease) (OR = 4.97 CI 95% [1.8-13.7] P = 0.002), initial serum creatinine ≥ 100 μmol/L (OR = 8.3 CI 95% [2.55-27.4] P = 0.0005), and dose cycle of cisplatin ≥ 100 mg/m(2) (OR = 10.8 CI 95% [3.6-32.5] P0.0001).Rapid outpatient administration of a single dose of cisplatin at ≥ 75 mg/m(2) is feasible without a high risk of nephrotoxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|